TAPENTADOL: POTENTIAL UNIQUE DUAL MECHANISM OF ACTION1

Tapentadol, the active molecule in NUCYNTA® ER , has been shown in preclinical and animal studies to activate the mu-opioid receptor (MOR) and inhibit reuptake of norepinephrine1*

Video animation depicting the unique mechanism of action of tapentadol

*Tapentadol is a centrally acting synthetic analgesic. The exact mechanism of action is unknown.

*Although the clinical relevance is unclear, preclinical studies have shown that tapentadol is an MOR agonist and a norepinephrine reuptake inhibitor (NRI). Analgesia in animal models is derived from both of these properties.

CONTRAINDICATIONS:

Significant respiratory depression; acute or severe bronchial asthma or hypercarbia in an unmonitored setting or in the absence of resuscitative equipment; known or suspected paralytic ileus; hypersensitivity (e.g., anaphylaxis, angioedema) to tapentadol or to any other ingredients of the product; concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days.

References
  1. NUCYNTA® (package insert). Titusville, NJ: Janssen Pharmaceuticals, Inc; 2009.